Drugs / Orforglipron
Orforglipron
Drug FDA approvedMarketed as Foundayo
Oral non-peptide GLP-1 receptor agonist·First approved·2026·1 brand
- Registered trials
- 36
- Ongoing
- 20/ 56%
- Completed
- 16
- Indications
- 2
Approved indications
| Indication |
|---|
| Weight loss in adults with obesity |
| Weight loss in adults with overweight and at least one weight-related comorbid condition |
Clinical trial landscape
36 registered studies reference this molecule or one of its brands. The split below shows how many are ongoing versus completed per phase.
| Phase | Total | Ongoing | Completed | Split |
|---|---|---|---|---|
| Phase 3 | 27 | 17 | 10 | |
| Phase 1 | 7 | 1 | 6 | |
| Phase 4 | 2 | 2 | 0 | |
| All phases | 36 | 20 | 16 |
Ongoing Completed Balance withdrawn, terminated, or status unreported.
Study records: ClinicalTrials.gov →
Mechanism of action
Binds and activates GLP-1 receptors in appetite-regulating brain regions to reduce food intake and delay gastric emptying.
Recent developments
Headlines link to the original publisher. Sources limited to a reviewed list of journals, regulators, and medical press.